Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00482521 · ClinicalTrials.gov registry record · Phase 1
CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment
A Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00482521 is a Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 42 participants.
The verdict
NCT00482521, a Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
RATIONALE: CC-4047 may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of CC-4047 in treating patients with advanced solid tumors that did not respond to treatment.
Interventions
- DRUG CC-4047
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2007-03 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00482521
The ClinicalTrials.gov registry entry for NCT00482521 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC-4047 is the first listed.
NCT00482521 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00482521 about?
NCT00482521 is a clinical study titled "CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment". RATIONALE: CC-4047 may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of CC-4047 in treating patients with advanced solid tumors that did not respond to treatment.
What is the current status of trial NCT00482521?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2007-03. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00482521?
The interventions under investigation include: CC-4047 (DRUG).
Who is sponsoring clinical trial NCT00482521?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.